SMT201600088B - Analoghi di buprenorfina come agonisti e/o antagonisti dei recettori degli oppioidi - Google Patents

Analoghi di buprenorfina come agonisti e/o antagonisti dei recettori degli oppioidi

Info

Publication number: SMT201600088B
Authority: SM; San Marino
Prior art keywords: opiousid; buprenorphine; agonists; analogues; antagonists
Prior art date: 2010-09-21

Application number

SM201600088T

Other languages

English (en)

Italian (it)

Inventor

Donald J Kyle

Laykea Tafesse

Original Assignee

Purdue Pharma Lp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-21

Filing date

2016-03-24

Publication date

2016-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44903285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600088(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-03-24 Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp

2016-04-29 Publication of SMT201600088B publication Critical patent/SMT201600088B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SM201600088T 2010-09-21 2016-03-24 Analoghi di buprenorfina come agonisti e/o antagonisti dei recettori degli oppioidi SMT201600088B (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US38491210P	2010-09-21	2010-09-21
US201161503674P	2011-07-01	2011-07-01
PCT/IB2011/002208 WO2012038813A1 (en)	2010-09-21	2011-09-20	Buprenorphine analogs

Publications (1)

Publication Number	Publication Date
SMT201600088B true SMT201600088B (it)	2016-04-29

Family

ID=44903285

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM201600088T SMT201600088B (it)	2010-09-21	2016-03-24	Analoghi di buprenorfina come agonisti e/o antagonisti dei recettori degli oppioidi

Country Status (34)

Country	Link
US (1)	US9221831B2 (es)
EP (1)	EP2619212B1 (es)
JP (2)	JP5977240B2 (es)
KR (2)	KR101630912B1 (es)
CN (2)	CN105399751A (es)
AR (1)	AR083062A1 (es)
AU (1)	AU2011306644B2 (es)
CA (1)	CA2810356C (es)
CL (1)	CL2013000732A1 (es)
CO (1)	CO6690803A2 (es)
CR (1)	CR20130129A (es)
CY (1)	CY1117227T1 (es)
DK (1)	DK2619212T3 (es)
DO (1)	DOP2013000060A (es)
EA (1)	EA201390422A1 (es)
EC (1)	ECSP13012543A (es)
ES (1)	ES2566828T3 (es)
HR (1)	HRP20160281T1 (es)
HU (1)	HUE027195T2 (es)
ME (1)	ME02367B (es)
MX (1)	MX2013003354A (es)
NI (1)	NI201300032A (es)
NZ (1)	NZ609200A (es)
PE (1)	PE20140020A1 (es)
PH (1)	PH12013500530A1 (es)
PL (1)	PL2619212T3 (es)
RS (1)	RS54579B1 (es)
SG (1)	SG188300A1 (es)
SI (1)	SI2619212T1 (es)
SM (1)	SMT201600088B (es)
TW (2)	TW201422621A (es)
UY (1)	UY33618A (es)
WO (1)	WO2012038813A1 (es)
ZA (1)	ZA201301217B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8852638B2 (en)	2005-09-30	2014-10-07	Durect Corporation	Sustained release small molecule drug formulation
JP2010531807A (ja)	2007-05-25	2010-09-30	トルマーセラピューティクス，インコーポレイテッド	リスペリドン化合物の徐放送達製剤
US9272044B2 (en)	2010-06-08	2016-03-01	Indivior Uk Limited	Injectable flowable composition buprenorphine
GB2513060B (en)	2010-06-08	2015-01-07	Rb Pharmaceuticals Ltd	Microparticle buprenorphine suspension
HUE026619T2 (en)	2010-06-15	2016-06-28	Gruenenthal Gmbh	Pharmaceutical combination for the treatment of pain
PL2707361T3 (pl)	2011-05-10	2018-01-31	Gilead Sciences Inc	Skondensowane związki heterocykliczne stosowane jako modulatory kanału sodowego
TWI622583B (zh)	2011-07-01	2018-05-01	基利科學股份有限公司	作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es)	2011-07-01	2018-04-28
WO2013084060A1 (en)	2011-12-08	2013-06-13	Purdue Pharma L.P.	Quaternized buprenorphine analogs
US9315514B2 (en) *	2012-08-27	2016-04-19	Rhodes Technologies	1,3-dioxanomorphides and 1,3-dioxanocodides
CA2890655A1 (en)	2012-11-09	2014-05-15	Purdue Pharma L.P.	Benzomorphan analogs and the use thereof
JP6317755B2 (ja) *	2012-12-07	2018-04-25	パーデュー、ファーマ、リミテッド、パートナーシップ	オピオイド受容体モジュレーターとしてのブプレノルフィン類似体
US9056836B2 (en)	2013-01-31	2015-06-16	Purdue Pharma L.P.	Benzomorphan analogs and the use thereof
US8969358B2 (en)	2013-03-15	2015-03-03	Purdue Pharma L.P.	Buprenorphine analogs
WO2015100092A2 (en) *	2013-12-26	2015-07-02	Purdue Pharma L.P.	7-beta analogs of orvinols
CN106414408A (zh)	2013-12-26	2017-02-15	普渡制药公司	缩合环吗啡喃和其用途
US9988392B2 (en)	2013-12-26	2018-06-05	Purdue Pharma L.P.	7-beta-alkyl analogs of orvinols
EP3087079B1 (en)	2013-12-26	2019-04-03	Purdue Pharma LP	Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015097547A1 (en)	2013-12-26	2015-07-02	Purdue Pharma L.P.	10-substituted morphinan hydantoins
WO2015099863A1 (en)	2013-12-27	2015-07-02	Purdue Pharma L.P.	6-substituted and 7-substituted morphinan analogs and the use thereof
GB201404139D0 (en)	2014-03-10	2014-04-23	Rb Pharmaceuticals Ltd	Sustained release buprenorphine solution formulations
WO2015183780A1 (en)	2014-05-27	2015-12-03	Purdue Pharma L.P.	Spirocyclic morphinans and use thereof
WO2015192053A1 (en)	2014-06-13	2015-12-17	Purdue Pharma L.P.	Azamophinan derivatives and use thereof
MA41125A (fr)	2014-12-05	2017-10-10	Purdue Pharma Lp	Dérivés de 6.7-cyclomorphinane et leur utilisation
KR20180080248A (ko) *	2015-10-26	2018-07-11	오르포메드, 인코포레이티드	부프레노르핀의 에틸렌 글리콜 에테르
BR112018014788B1 (pt) *	2016-03-22	2022-03-22	Helsinn Healthcare Sa	Composto e uso de um composto
US10745402B2 (en)	2017-01-02	2020-08-18	Purdue Pharma L.P.	Morphinan derivatives and use thereof
CA3063975A1 (en)	2017-05-19	2018-11-22	River Stone Biotech Aps	Preparation of buprenorphine
JP2021104932A (ja) *	2018-03-30	2021-07-26	日本ケミファ株式会社	モルヒナン誘導体の製造方法
WO2024044179A1 (en) *	2022-08-23	2024-02-29	Virginia Commonwealth University	Multiple targeting opioid receptor ligands as novel analgesics with minimum abuse liability
AU2024250576A1 (en) *	2023-04-04	2025-11-13	Board Of Regents, The University Of Texas System	METHODS OF SYNTHESIZING 14-β-AMINOMORPHANS AND SALTS THEREOF

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1136764A (en)	1965-08-13	1968-12-18	Reckitt & Sons Ltd	Derivatives of thebaine and oripavine
DE69826278T2 (de)	1997-05-30	2005-11-10	Banyu Pharmaceutical Co., Ltd.	2-oxoimidazol-derivate
SK14272000A3 (sk)	1998-03-26	2001-05-10	Japan Tobacco Inc.	Antagonista nociceptínu, derivát amidu, farmaceutický prostriedok, spôsob, použitie a komerčné balenie
BR0207978A (pt)	2001-03-02	2004-03-02	Euro Celtique Sa	N-but-3enil norbuprenorfina e métodos de uso
US6740641B2 (en)	2001-07-27	2004-05-25	Euro-Celtique, S.A.	Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
NZ538726A (en)	2002-09-25	2006-11-30	Euro Celtique S	N-substituted hydromorphones and the use thereof
EP1554290B1 (en)	2002-10-25	2009-09-30	Euro-Celtique S.A.	Analogs and prodrugs of buprenorphine
US7202259B2 (en)	2002-11-18	2007-04-10	Euro-Celtique S.A.	Therapeutic agents useful for treating pain
US6958398B1 (en)	2002-12-30	2005-10-25	Euro-Celtique S.A.	Methods for making thebaine or its acid salts
US8481743B2 (en)	2006-11-01	2013-07-09	Purdue Pharma L.P.	Phenylpropionamide compounds and the use thereof
GB2447014A (en) *	2007-03-01	2008-09-03	Reckitt Benckiser Healthcare	Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
NZ586058A (en)	2007-11-30	2013-11-29	Purdue Pharma Lp	Benzomorphan compounds
EP2703404A1 (en)	2008-07-30	2014-03-05	Purdue Pharma L.P.	Buprenorphine analogs
WO2013072758A1 (en)	2011-11-15	2013-05-23	Purdue Pharma L.P.	Pyrimidine diol amides as sodium channel blockers
WO2013084060A1 (en)	2011-12-08	2013-06-13	Purdue Pharma L.P.	Quaternized buprenorphine analogs
WO2013167963A1 (en)	2012-05-11	2013-11-14	Purdue Pharma L.P.	Benzomorphan compounds as opioid receptors modulators
US9315514B2 (en)	2012-08-27	2016-04-19	Rhodes Technologies	1,3-dioxanomorphides and 1,3-dioxanocodides
CA2890655A1 (en)	2012-11-09	2014-05-15	Purdue Pharma L.P.	Benzomorphan analogs and the use thereof
JP6317755B2 (ja)	2012-12-07	2018-04-25	パーデュー、ファーマ、リミテッド、パートナーシップ	オピオイド受容体モジュレーターとしてのブプレノルフィン類似体
EP2931724B1 (en)	2012-12-14	2017-01-25	Purdue Pharma LP	Pyridonemorphinan analogs and biological activity on opioid receptors
US8937084B2 (en)	2012-12-14	2015-01-20	Purdue Pharma L.P.	Nitrogen containing morphinan derivatives and the use thereof
TW201434837A (zh)	2012-12-14	2014-09-16	Purdue Pharma Lp	螺環嗎啡喃及其用途
EP2941431B1 (en)	2012-12-28	2017-10-25	Purdue Pharma L.P.	Substituted morphinans and the use thereof
WO2014102587A1 (en)	2012-12-28	2014-07-03	Purdue Pharma L.P.	7,8-cyclicmorphinan analogs
US9056836B2 (en)	2013-01-31	2015-06-16	Purdue Pharma L.P.	Benzomorphan analogs and the use thereof
US8969358B2 (en)	2013-03-15	2015-03-03	Purdue Pharma L.P.	Buprenorphine analogs
US9340542B2 (en)	2013-12-26	2016-05-17	Purdue Pharma L.P.	Propellane-based compounds and the use thereof
WO2015097547A1 (en)	2013-12-26	2015-07-02	Purdue Pharma L.P.	10-substituted morphinan hydantoins
WO2015100092A2 (en)	2013-12-26	2015-07-02	Purdue Pharma L.P.	7-beta analogs of orvinols
US9988392B2 (en)	2013-12-26	2018-06-05	Purdue Pharma L.P.	7-beta-alkyl analogs of orvinols
WO2015099863A1 (en)	2013-12-27	2015-07-02	Purdue Pharma L.P.	6-substituted and 7-substituted morphinan analogs and the use thereof
WO2015102682A1 (en)	2013-12-30	2015-07-09	Purdue Pharma L.P.	Pyridone-sulfone morphinan analogs as opioid receptor ligands

2011
- 2011-09-20 CN CN201510733006.4A patent/CN105399751A/zh active Pending
- 2011-09-20 PH PH1/2013/500530A patent/PH12013500530A1/en unknown
- 2011-09-20 CA CA2810356A patent/CA2810356C/en not_active Expired - Fee Related
- 2011-09-20 WO PCT/IB2011/002208 patent/WO2012038813A1/en not_active Ceased
- 2011-09-20 KR KR1020137009943A patent/KR101630912B1/ko not_active Expired - Fee Related
- 2011-09-20 ES ES11776855.6T patent/ES2566828T3/es active Active
- 2011-09-20 AU AU2011306644A patent/AU2011306644B2/en not_active Ceased
- 2011-09-20 NZ NZ609200A patent/NZ609200A/en not_active IP Right Cessation
- 2011-09-20 DK DK11776855.6T patent/DK2619212T3/en active
- 2011-09-20 US US13/825,241 patent/US9221831B2/en active Active
- 2011-09-20 HR HRP20160281TT patent/HRP20160281T1/hr unknown
- 2011-09-20 KR KR20157004529A patent/KR20150027315A/ko not_active Withdrawn
- 2011-09-20 JP JP2013529723A patent/JP5977240B2/ja not_active Expired - Fee Related
- 2011-09-20 UY UY0001033618A patent/UY33618A/es unknown
- 2011-09-20 SG SG2013014113A patent/SG188300A1/en unknown
- 2011-09-20 CN CN2011800450775A patent/CN103154000A/zh active Pending
- 2011-09-20 PE PE2013000548A patent/PE20140020A1/es not_active Application Discontinuation
- 2011-09-20 EA EA201390422A patent/EA201390422A1/ru unknown
- 2011-09-20 AR ARP110103431A patent/AR083062A1/es unknown
- 2011-09-20 HU HUE11776855A patent/HUE027195T2/en unknown
- 2011-09-20 EP EP11776855.6A patent/EP2619212B1/en active Active
- 2011-09-20 MX MX2013003354A patent/MX2013003354A/es not_active Application Discontinuation
- 2011-09-20 SI SI201130750T patent/SI2619212T1/sl unknown
- 2011-09-20 ME MEP-2016-38A patent/ME02367B/me unknown
- 2011-09-20 PL PL11776855.6T patent/PL2619212T3/pl unknown
- 2011-09-20 RS RS20160119A patent/RS54579B1/sr unknown
- 2011-09-21 TW TW102147960A patent/TW201422621A/zh unknown
- 2011-09-21 TW TW100133950A patent/TW201242968A/zh unknown
2013
- 2013-02-18 ZA ZA2013/01217A patent/ZA201301217B/en unknown
- 2013-03-18 CL CL2013000732A patent/CL2013000732A1/es unknown
- 2013-03-20 NI NI201300032A patent/NI201300032A/es unknown
- 2013-03-20 DO DO2013000060A patent/DOP2013000060A/es unknown
- 2013-03-21 CR CR20130129A patent/CR20130129A/es not_active Application Discontinuation
- 2013-04-05 EC ECSP13012543 patent/ECSP13012543A/es unknown
- 2013-04-18 CO CO13100225A patent/CO6690803A2/es unknown
2015
- 2015-11-19 JP JP2015226945A patent/JP2016102115A/ja not_active Withdrawn
2016
- 2016-03-04 CY CY20161100187T patent/CY1117227T1/el unknown
- 2016-03-24 SM SM201600088T patent/SMT201600088B/xx unknown

Also Published As

Publication number	Publication date
TW201242968A (en)	2012-11-01
NZ609200A (en)	2015-01-30
CO6690803A2 (es)	2013-06-17
ES2566828T3 (es)	2016-04-15
US9221831B2 (en)	2015-12-29
HUE027195T2 (en)	2016-10-28
ECSP13012543A (es)	2013-06-28
HK1187045A1 (en)	2014-03-28
DK2619212T3 (en)	2016-03-21
JP2016102115A (ja)	2016-06-02
MX2013003354A (es)	2013-06-24
WO2012038813A1 (en)	2012-03-29
CA2810356A1 (en)	2012-03-29
CR20130129A (es)	2013-08-29
PH12013500530A1 (en)	2017-08-09
CN105399751A (zh)	2016-03-16
AU2011306644B2 (en)	2015-07-02
DOP2013000060A (es)	2013-04-30
CY1117227T1 (el)	2017-04-05
CN103154000A (zh)	2013-06-12
RS54579B1 (sr)	2016-06-30
EP2619212B1 (en)	2016-01-06
AR083062A1 (es)	2013-01-30
KR20130097210A (ko)	2013-09-02
US20140057931A1 (en)	2014-02-27
ZA201301217B (en)	2013-09-25
CA2810356C (en)	2016-06-14
KR20150027315A (ko)	2015-03-11
SG188300A1 (en)	2013-04-30
SI2619212T1 (sl)	2016-04-29
AU2011306644A1 (en)	2013-04-11
UY33618A (es)	2012-03-30
KR101630912B1 (ko)	2016-06-15
JP2013543488A (ja)	2013-12-05
NI201300032A (es)	2014-01-13
HRP20160281T1 (hr)	2016-04-08
EP2619212A1 (en)	2013-07-31
PL2619212T3 (pl)	2016-09-30
EA201390422A1 (ru)	2014-01-30
JP5977240B2 (ja)	2016-08-24
TW201422621A (zh)	2014-06-16
ME02367B (me)	2016-06-20
CL2013000732A1 (es)	2013-07-26
PE20140020A1 (es)	2014-01-31

Publication	Publication Date	Title
SMT201600088B (it)	2016-04-29	Analoghi di buprenorfina come agonisti e/o antagonisti dei recettori degli oppioidi
EP2585064A4 (en)	2014-01-15	C5aR Antagonist
CY2020018I1 (el)	2020-11-25	Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων
DK2821407T3 (da)	2017-01-02	Piperidinoncarboxamidazaindan-cgrp receptorantagonister
EP2381778A4 (en)	2012-09-05	C5aR Antagonist
EP2934516A4 (en)	2016-07-20	3 ESTER 4 SUBSTITUTED OREXINE RECEPTOR ANTAGONISTS
EP2964226A4 (en)	2016-08-10	2-pyridyloxy-4-ESTER-orexin receptor antagonists
EP2911675A4 (en)	2016-06-01	2-PYRIDYLOXY-3-SUBSTITUTED 4-NITRIL-OREXINE RECEPTOR ANTAGONISTS
EP2908812A4 (en)	2016-04-20	2-pyridyloxy, 3-ESTER-4-NITRILOREXIN receptor antagonists
EP2619204A4 (en)	2014-08-27	TRIAZOLOPYRAZINONE AS P2X7 RECEPTOR ANTAGONISTS
IL226491A0 (en)	2013-07-31	Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
PT2585437E (pt)	2014-04-29	Compostos de tioacetato, composições e métodos de uso
EP2771001A4 (en)	2015-03-25	PIPERIDINYL-alkyne-orexin
EP2803662A4 (en)	2015-06-03	P2X4 Receptor Antagonists
IL245471B (en)	2018-03-29	Fluorinated compounds as alpha v integrin receptor antagonists
ZA201105323B (en)	2012-03-28	Agonists and antagonists of the sip5 receptor,and methods of uses thereof
BR112013006016A2 (pt)	2016-06-07	compostos de azabenzotiazol, composições e métodos de uso
EP2709991A4 (en)	2014-10-01	USE OF CXCR4 ANTAGONISTS
EP2721016A4 (en)	2014-10-08	TRPV4 Antagonist
SMT201700064B (it)	2017-03-08	Antagonisti di d2, metodi di sintesi e metodi di uso
BR112013022552A2 (pt)	2016-12-06	compostos de quinazolina substituídos com alcino e métodos de uso
SMT201500296B (it)	2016-01-08	Antagonisti del recettore trpm8
BR112014012409A2 (pt)	2017-06-13	composições de buprenorfina e antagonistas do receptor mu-opiódie
PT2793883T (pt)	2018-07-18	Antagonistas de trpm8
EP2771346A4 (en)	2015-06-03	ISOXAZOLOPYRIDIN-orexin